Inventor · disambiguated record
Peter L. Nara
Also filed as: NARA PETER · NARA PETER L
12 granted patents·12 pending applications·201 citations·filing 1990–2023
92Inventor score
Top patents by PatentIndex Score
24 records- 0184US9872899B2Immunogenic human rhinovirus (HRV) compositionsBIOLOGICAL MIMETICS INC·Filed 2014·Granted Jan 23, 2018·5 cites·10 claims
- 0281US5585250ADampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapiesUS HEALTH·Filed 1993·Granted Dec 17, 1996·42 cites·12 claims
- 0378US5853724ADampening of an immunodominant epitope of an antigen for use in plant, animal and human vaccines and immunotherapiesUS HEALTH·Filed 1996·Granted Dec 29, 1998·41 cites·14 claims
- 0470US5668149AInhibition of human immunodeficiency virus-1 infectivity in human cellsUS ARMY·Filed 1990·Granted Sep 16, 1997·44 cites·4 claims
- 0568US11260122B2Immunogenic influenza compositionBIOLOGICAL MIMETICS INC·Filed 2019·Granted Mar 1, 2022·0 cites·18 claims
- 0667US6294322B1Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1US HEALTH·Filed 1993·Granted Sep 25, 2001·20 cites·5 claims
- 0764US5932218AMultideterminant peptides eliciting helper T-lymphocyte, cytotoxic T-lymphocyte, and neutralizing antibody responses against HIV-1US HEALTH·Filed 1995·Granted Aug 3, 1999·21 cites·2 claims
- 0864US2025289872A1Formulation for antigen-binding molecules that bind to porphyromonas gingivalisK BIO INVEST LLC·Filed 2023·Application pending·0 cites
- 0962US2023365662A1Antigen-binding molecules that bind to porphyromonas gingivalisKEYSTONE BIO INC·Filed 2022·Application pending·0 cites
- 1060US10286061B2Immunogenic influenza compositionBIOLOGICAL MIMETICS INC·Filed 2015·Granted May 14, 2019·0 cites·13 claims
- 1160US2011177121A1Immunogenic Influenza CompositionBIOLOG MIMETICS INC·Filed 2009·Application pending·0 cites
- 1260US2019275137A1Immunogenic Influenza CompositionBIOLOGICAL MIMETICS INC·Filed 2019·Application pending·0 cites
- 1358US7094405B1Peptides which elicit a high neutralizing antibody titer, cytotoxic T lymphocyte response and T helper cell response in a broad range of MHC type recipientsUS HEALTH·Filed 1999·Granted Aug 22, 2006·14 cites·7 claims
- 1457US2025334585A1Diagnostics for porphyromonas gingivalisKEYSTONE BIO INC·Filed 2022·Application pending·0 cites
- 1557US2023330208A1Immunogenic Human Rhinovirus (HRV) CompositionBIOLOGICAL MIMETICS INC·Filed 2022·Application pending·0 cites
- 1657US2022226454A1Antigenic composition(s) and method(s) of use against porphyromonas gingivalis for the prevention and/or treatment of infection and/or diseasesKEYSTONE BIO INC·Filed 2022·Application pending·0 cites
- 1757US2024400654A1Antigen-binding molecules that bind to porphyromonas gingivalisKEYSTONE BIO INC·Filed 2021·Application pending·0 cites
- 1856US2021085780A1Immunogenic Human Rhinovirus (HRV) CompositionBIOLOGICAL MIMETICS INC·Filed 2020·Application pending·0 cites
- 1954US2014004149A1Immunogenic Influenza CompositionTOBIN GREGORY·Filed 2011·Application pending·0 cites
- 2053US10300125B2Immunogenic influenza compositionBIOLOGICAL MIMETICS INC·Filed 2015·Granted May 28, 2019·0 cites·19 claims
- 2150US2022265808A1A porcine circovirus type 2 (pcv2) vaccineNDSU RES FOUNDATION·Filed 2020·Application pending·0 cites
- 2249US2018064802A1Immunogenic Human Rhinovirus (HRV) CompositionBIOLOGICAL MIMETICS INC·Filed 2017·Application pending·0 cites
- 2348US5484889APlant protein useful for treating tumors and HIV infectionUNIV NEW YORK·Filed 1994·Granted Jan 16, 1996·9 cites·1 claims
- 2443US6214347B1Multideterminant peptides that elicit helper T-lymphocyte, cytotoxic T lymphocyte and neutralizing antibody responses against HIV-1US HEALTH·Filed 1995·Granted Apr 10, 2001·5 cites·1 claims
Join the waitlist — get patent alerts
Get an alert when Peter L. Nara files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →